While X4 Pharmaceuticals Inc has overperformed by 0.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, XFOR fell by -82.23%, with highs and lows ranging from $26.83 to $1.35, whereas the simple moving average fell by -3.65% in the last 200 days.
On December 05, 2025, Stifel started tracking X4 Pharmaceuticals Inc (NASDAQ: XFOR) recommending Buy. A report published by B. Riley Securities on December 12, 2023, Downgraded its rating to ‘Neutral’ for XFOR. B. Riley Securities also rated XFOR shares as ‘Buy’, setting a target price of $3 on the company’s shares in an initiating report dated August 30, 2023. Cantor Fitzgerald Initiated an Overweight rating on December 22, 2022, and assigned a price target of $3. Piper Sandler initiated its ‘Overweight’ rating for XFOR, as published in its report on December 12, 2022. Oppenheimer’s report from December 23, 2019 suggests a price prediction of $20 for XFOR shares, giving the stock a ‘Outperform’ rating. ROTH Capital also rated the stock as ‘Buy’.
Analysis of X4 Pharmaceuticals Inc (XFOR)
Further, the quarter-over-quarter increase in sales is 215.18%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of X4 Pharmaceuticals Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -156.87% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.48, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and XFOR is recording an average volume of 889.57K. On a monthly basis, the volatility of the stock is set at 7.50%, whereas on a weekly basis, it is put at 7.87%, with a loss of -1.76% over the past seven days. Furthermore, long-term investors anticipate a median target price of $8.00, showing growth from the present price of $3.91, which can serve as yet another indication of whether XFOR is worth investing in or should be passed over.
How Do You Analyze X4 Pharmaceuticals Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 10.44%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 32.31% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
